Skip to main content

Renal Diseases Drug Development Pipeline Review 2018 – AdAlta , Allena Pharmaceuticals , apceth Biopharma , Arch Biopartners , Astellas Pharma , AstraZeneca , Bayer

This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.
Some of Key Players are: 
AdAlta , Allena Pharmaceuticals , apceth Biopharma , Arch Biopartners , Astellas Pharma , AstraZeneca , Bayer , BiOrion Technologies , Boehringer Ingelheim , Boryung Pharmaceutical , Celgene , Certa Therapeutics , Conatus Pharmaceuticals , Corvidia Therapeutics , DiaMedica Therapeutics , Dimerix Bioscience , DiscoveryBiomed , DURECT C, Epigen Biosciences , Galectin Therapeutics , GenKyoTex , GNI Group , iBio Inc, IC-MedTech , Ipsen , Isarna Therapeutics , KBP BioSciences , Kidney Fibrosis, Klotho Therapeutics , Les Laboratoires Servier ,
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.
Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.
Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.
Scope
- Which companies are the most active within each pipeline-
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
- What are the most important R&D milestones and data publications to have happened in this disease area-
 Table of Contents
1 Table of Contents 
1.1 List of Tables
1.2 List of Figures
2 Introduction 
2.1 Renal Diseases Report Coverage
2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview
2.3 Kidney Fibrosis - Overview
2.4 Polycystic Kidney Disease - Overview
2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
3 Therapeutics Development 
3.1 Chronic Kidney Disease (Chronic Renal Failure)
3.2 Kidney Fibrosis
3.3 Polycystic Kidney Disease
3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
4 Therapeutics Assessment 
4.1 Chronic Kidney Disease (Chronic Renal Failure)
4.2 Kidney Fibrosis
4.3 Polycystic Kidney Disease
4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
5 Companies Involved in Therapeutics Development 
5.1 Chronic Kidney Disease (Chronic Renal Failure)
5.2 Kidney Fibrosis
5.3 Polycystic Kidney Disease
5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
6 Dormant Projects 
6.1 Chronic Kidney Disease (Chronic Renal Failure)
6.2 Kidney Fibrosis
6.3 Polycystic Kidney Disease
6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
7 Discontinued Products 
7.1 Chronic Kidney Disease (Chronic Renal Failure)
7.2 Kidney Fibrosis
7.3 Polycystic Kidney Disease
7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
8 Product Development Milestones 
8.1 Chronic Kidney Disease (Chronic Renal Failure)
8.2 Kidney Fibrosis
8.3 Polycystic Kidney Disease
9 Appendix 
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

Comments

Popular posts from this blog

Digital Marketing Market to Witness Robust Expansion throughout the Forecast Period 2019–2026

Digital marketing is the marketing of products or services using digital technologies, mainly on the Internet, but also including mobile phones, display advertising,and any other digital medium. Digital marketing channels are systems based on the internet that can create, accelerate, and transmit product value from producer to the terminal consumer by digital networks. Digital marketing’s development since the 1990s and 2000s has changed the way brands and businesses use technology for marketing. As digital platforms are increasingly incorporated into marketing plans and everyday life, and as people use digital devices instead of visiting physical shops, digital marketing campaigns are becoming more prevalent and efficient. Digital Marketing Market report provides in-depth statistics and analysis available on the market status of the Digital Marketing Manufacturers and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering...

Disaster Recovery Solution Market 2018 by Emerging Trend, High Demand, Supply Scenarios and Business Development 2022 – IBM Corporation , SunGard Availability Services , Microsoft Corporation

Disaster Recovery Solution Market report provides in-depth statistics and analysis available on the market status of the Disaster Recovery Solution Manufacturers and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Disaster Recovery Solution market. It contains the analysis of drivers, challenges, and restraints impacting the industry. Disaster Recovery Solution Market report also provide a thorough understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, challenges, and opportunities in the Disaster Recovery Solution Market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of the products/services from the past three years. Moreover, the report also offers a 360º outlook of the market through the comp...

Healthcare IT Consulting Market Outlook 2017-2023 by Key Players – ALLSCRIPTS HEALTHCARE SOLUTIONS, Cerner Corporation, Cognizant Technology Solutions, Deloitte Touche Tohmatsu Limited

Global Healthcare IT Consulting Market is accounted for $15.69 billion in 2016 and expected to grow at a CAGR of 20.2% to reach $56.9 billion by 2023. The market is driven by rapid growth in digitization of healthcare, rapidly changing HCIT landscape, government support for healthcare IT solutions, growing HCIT expenditure, growing venture capital investments in health IT, and the need for data security are driving the growth of this market. However, concerns regarding data confidentiality will hamper market growth. Furthermore, cloud consulting, increasing consolidation in the healthcare industry, opportunities in small rural hospitals and need for healthcare IT consultants in emerging economies is providing lot of opportunities. Major Key Players of the Healthcare IT Consulting Market are:  ALLSCRIPTS HEALTHCARE SOLUTIONS, Cerner Corporation, Cognizant Technology Solutions, Deloitte Touche Tohmatsu Limited, Epic Systems Corporation, General electric (GE) company, IBM Corporat...